Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies

CAR-T Digest - August 2020

04 June 2026: Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio has strengthened its position in the next wave of ADC innovation through a multi-target licensing agreement with Lonza, gaining access to a clinically validated ADC platform that could accelerate the development of highly differentiated precision oncology therapies
The collaboration leverages Stipple Bio’s Pointillist Platform, to identify highly tumor-specific targets, aiming to enhance ADC efficacy while minimizing off-target toxicities
By combining this epitope-level targeting approach with Lonza’s proven GlycoConnect, HydraSpace, and toxSYN technologies, the partnership creates a powerful framework for designing ADCs with improved selectivity, therapeutic index, and manufacturability, potentially enabling both first-in-class and best-in-class opportunities
The agreement also provides strategic validation of Stipple Bio’s lead program, STP-100, while reducing platform-development risk through access to technologies that have already demonstrated clinical and manufacturing readiness, allowing the company to focus resources on target discovery and clinical execution
Strategically, this collaboration reflects a growing industry shift from simply identifying new targets to engineering greater precision at the epitope level, suggesting that future ADC leaders may be defined not only by what they target, but by how selectively they engage cancer cells while sparing healthy tissue